Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Firdapse | amifampridine phosphate | Lambert-Eaton Myasthenic Syndrome, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
| Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Complete | ||
| Banzel | Rufinamide | Lennox-Gastaut syndrome | List with clinical criteria and/or conditions | Complete | ||
| Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Active | ||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
| Imbruvica | ibrutinib | Leukemia | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed |
Last Updated : May 17, 2024